41 – 50 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.
(
- Contribution to journal › Article
- 2010
-
Mark
Utility-based outcomes made easy: The number needed per QALY gained (NNQ). Observational cohort study from Southern Sweden of TNF blockade in inflammatory arthritis.
(
- Contribution to journal › Article
-
Mark
Open access publishing. And now, e-publication bias
(
- Contribution to journal › Letter
-
Mark
Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register
(
- Contribution to journal › Article
-
Mark
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
(
- Contribution to journal › Article
- 2009
-
Mark
Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
(
- Contribution to journal › Article
- 2008
-
Mark
Anti-TNF treatment of chronic arthritis in clinical practice. New assessment method and predictors of efficacy and tolerability.
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article